<SEC-DOCUMENT>0001140361-23-050569.txt : 20231031
<SEC-HEADER>0001140361-23-050569.hdr.sgml : 20231031
<ACCEPTANCE-DATETIME>20231031215640
ACCESSION NUMBER:		0001140361-23-050569
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20231027
FILED AS OF DATE:		20231031
DATE AS OF CHANGE:		20231031

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI Group Ltd.
		CENTRAL INDEX KEY:			0001958461

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231366365

	BUSINESS ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023
		BUSINESS PHONE:		81-3-6214-3600

	MAIL ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI USA, Inc.
		CENTRAL INDEX KEY:			0001973229

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231366364

	BUSINESS ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-284-0324

	MAIL ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GYRE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE, SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		650-266-8674

	MAIL ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE, SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20150820

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-10-27</periodOfReport>

    <issuer>
        <issuerCik>0001124105</issuerCik>
        <issuerName>GYRE THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>GYRE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001958461</rptOwnerCik>
            <rptOwnerName>GNI Group Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>NIHONBASHI-HONCHO YS BLDG 3F</rptOwnerStreet1>
            <rptOwnerStreet2>2-2-2 NIHONBASHI-HONCHO, CHUO-KU</rptOwnerStreet2>
            <rptOwnerCity>TOKYO</rptOwnerCity>
            <rptOwnerState>M0</rptOwnerState>
            <rptOwnerZipCode>103-0023</rptOwnerZipCode>
            <rptOwnerStateDescription>JAPAN</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001973229</rptOwnerCik>
            <rptOwnerName>GNI USA, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>12730 HIGH BLUFF DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE 250</rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92130</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Series X Convertible Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-10-27</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>811</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4915</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>811000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13151</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
        <derivativeTransaction>
            <securityTitle>
                <value>Series X Convertible Preferred Stock Warrant (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F4"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-10-27</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>8110300</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.125</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2023-10-30</value>
            </exerciseDate>
            <expirationDate>
                <value>2033-10-30</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Series X Convertible Preferred Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>811</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>8110300</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the &quot;Preferred Stock&quot;), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).</footnote>
        <footnote id="F2">The Preferred Stock has no expiration date.</footnote>
        <footnote id="F3">These securities are held by GNI USA, Inc., a Delaware corporation (&quot;GNI USA&quot;) which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&quot;GNI Japan&quot;). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.</footnote>
        <footnote id="F4">These warrants have an exercise price of $4,915.00 per share of Preferred Stock.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.</signatureName>
        <signatureDate>2023-10-31</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI USA, Inc.</signatureName>
        <signatureDate>2023-10-31</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
